Toujeo ‘significantly lowers blood glucose’
The insulin glargine Toujeo has been found to be just as effective as insulin degludec in the first head-to-head randomised clinical trial.
The primary objective of the BRIGHT study was to determine if the effect of Sanofi’s Toujeo on blood sugar levels (HbA1c) was similar to insulin degludec.
The secondary objectives of the research included looking at the percentage of people who experienced adverse events, the total number of participants with low blood sugar events and the rate at which low blood sugar events occurred.
The trial specifically followed 929 adults whose type 2 diabetes was previously uncontrolled on non-insulin medication.
Riccardo Perfetti, head of the global diabetes medical team at Sanofi, said: “The most recently introduced long-acting insulins have already demonstrated significant blood glucose lowering benefit to adult patients with diabetes. From the perspective of physicians and patients, hypoglycemia remains a major limiting factor in effective blood sugar management in diabetes.
“We believe that these first comparative clinical data assessing similarity and difference not only in efficacy, but also in the important safety aspect, such as low blood sugar events, can support physicians in their treatment decisions.”
The BRIGHT study included adults with type 2 diabetes who had failed to control their HbA1c levels with oral antihyperglycemic drugs (OADs) with or without a glucagon-like peptide-1 (GLP-1) receptor agonist.Additional secondary endpoints included the percentage of participants requiring rescue therapy, safety, and patient-reported outcomes measured using the Diabetes Treatment Satisfaction Questionnaire (DTSQ, status version and change version) and the Hypoglycemic Attitudes and Behavior Scale.